Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
about
Enzyme replacement therapy for Anderson-Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseCerebral small vessel disease: Capillary pathways to stroke and cognitive declineAgalsidase alfa: a review of its use in the management of Fabry diseaseInner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapyNeuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseAutonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function testsEstablishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapyStroke and Fabry disease.Update on role of agalsidase alfa in management of Fabry disease.Fabry disease: recent advances in enzyme replacement therapy.Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.Novel therapeutic targets for the treatment of Fabry disease.Fabry disease-often seen, rarely diagnosed.Inherited metabolic disorders and cerebral infarction.Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease.Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Fabry disease: overall effects of agalsidase alfa treatment.Functional transcranial Doppler: presymptomatic changes in Fabry disease.Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.Cerebral hemodynamic changes in obstructive sleep apnea syndrome after continuous positive airway pressure treatment.White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up.Fabry disease and Factor V Leiden: a potent vascular risk combination.Therapeutic goals in the treatment of Fabry disease.Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment.Fabry disease in unselected patients with TIA or stroke: population-based study.Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease.Fabry disease
P2860
Q24200877-D3339055-6AB1-4701-B471-A22AC7FE6A5CQ24235483-5530E0D7-32FC-4E99-B4F8-A88303CAA2A6Q26471010-C6AC0802-7D78-4B7C-8C0F-6E93583C6293Q26776375-96E688D9-4934-4C97-97D4-25963A8941D2Q28274194-D75690AA-DE42-42B4-9D7A-31FE13F44929Q30481028-9AA1C76C-865A-4F5B-A957-D6E1B77B8D5FQ30501578-16039859-66F4-4346-A953-5CE78C457108Q33596689-5E1CD652-4602-48E7-87EA-47869595B4CEQ33831482-A480A66D-65F8-4D55-8836-58CE1C64117EQ33847189-0277BFC1-72F0-4626-A2ED-87B0B907A14CQ34061632-0ED3FC25-1FBA-4A30-979F-F669525580FBQ34883178-17221737-EB5D-424D-A769-DCE378D33BA3Q34974879-3FF3162A-91E4-4A82-97A5-6CD17F433473Q35147741-542647FF-0D3A-4760-8E4D-64BE1A486018Q35768834-6C9EB6DE-7870-44EC-B33D-5E2D2ADD4835Q36607211-265FD255-8548-4974-A16E-5D05E8776DE4Q36822452-F54EAB08-22C5-4A27-8E8D-3668360125ABQ37246955-DD6DA68C-9095-4519-BAB1-E0CF2C305B40Q37318161-1BDB7DBA-C7BC-4114-B5A8-DBBA6450A757Q37521065-507D34D9-1092-4B83-BDE9-11EB64B8CAE2Q37775790-19F6E8C3-14AF-4B1E-A2E4-331A7ABE6F19Q37801828-A524E5EA-3D16-49C0-8C21-7E3CE6C38246Q37994740-E302EC5B-4E6C-4024-9298-BBB942C3582EQ45192336-12BAE962-A99B-468E-A2A7-3CC8C0827FF2Q46223558-E8C2E56C-7597-40A7-B83A-6682AD7CB95BQ46735411-D746E6D2-51B7-47D2-87FB-28FEFE96696BQ48174332-BE7B431C-2D1D-4BB6-BE6F-8B66C16C39DBQ48389923-EA57E657-D255-49D3-87A8-B1E170BC8B71Q48664517-EB6AC30A-4E1C-4883-91A0-0E57A1ED85C4Q50436079-67016CC2-6BB3-40A9-8B92-F43C9536DF72Q51357161-52785FB4-36D4-4D82-A73E-9D81EBAA6B30Q54312694-7F9088D9-F2C9-4F34-82B1-7F945D32F47DQ54531507-BB90D611-4371-4CEB-9D13-E7391E957C3AQ56905945-E6A2A126-62E9-4092-A626-B726DE73C56D
P2860
Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@en
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@nl
type
label
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@en
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@nl
prefLabel
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@en
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@nl
P2093
P356
P1433
P1476
Elevated cerebral blood flow v ...... rsal after enzyme replacement.
@en
P2093
David F Moore
Geoffrey S F Ling
Gheona Altarescu
Gustavo Charria-Ortiz
Karen P Frei
Neal Jeffries
Raphael Schiffmann
Raymond Ferri
Roscoe O Brady
Thais Weibel
P304
P356
10.1161/HS0202.102601
P407
P577
2002-02-01T00:00:00Z